Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting
REDWOOD CITY, Calif., May 18, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new nonclinical data supporting the use of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting in Los Angeles, California. Ixo-vec is currently being evaluated in the Phase 2 LUNA trial in wet age-related macular degeneration (wet AMD). The data being presented at ASGCT are featured in an oral presentation on the identification of dose-dependent immune landscape signatures in nonhuman primates (NHPs), an oral presentation of nonclinical data that supports the potential for staggered, bilateral dosing of Ixo-vec and a poster presentation evaluating Ixo-vec per cell vector genome (vg) biodistribution and mRNA expression in NHPs.
Related news for (ADVM)
- Today’s Top Performers: MoBot’s Market Review 10/24/25 08:00 AM
- MoBot’s Stock Market Highlights – 09/23/25 11:00 AM
- Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones
- Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
- Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements